Dolphin Medical Services (BOM:526504) Research & Development: ₹0.00 Mil (TTM As of Mar. 2026)


BOM:526504 Dolphin Medical Services Ltd BOM:526504
36 GF Score
Price ₹8.69
GF Value ₹2.38
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Dolphin Medical Services Research & Development?

Dolphin Medical Services BOM:526504 36 Research & Development is ₹0.00 Mil as of Mar. 2026. GuruFocus rates BOM:526504 with a GF Score™ of 36/100 and a GF Value™ of ₹2.38 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dolphin Medical Services's Research & Development for the three months ended in Mar. 2026 was ₹0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.00 Mil.

Dolphin Medical Services  (BOM:526504) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Dolphin Medical Services Research & Development Related Terms

Dolphin Medical Services Research & Development Historical Data

* Premium members only.

The historical data trend for Dolphin Medical Services's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dolphin Medical Services Research & Development Chart

Dolphin Medical Services Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Dolphin Medical Services Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:526504
36GF Score
Dolphin Medical Services Ltd BOM:526504
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dolphin Medical Services Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.00 Mil mean?
Dolphin Medical Services (BOM:526504) has a Research & Development of ₹0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Dolphin Medical Services and its competitors.
Is Dolphin Medical Services' Research & Development too high?
Dolphin Medical Services' current Research & Development is ₹0.00 Mil. Overall, Dolphin Medical Services has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' Research & Development compare to TMO and DHR?
Dolphin Medical Services' Research & Development of ₹0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dolphin Medical Services and its competitors. Dolphin Medical Services's current Research & Development is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.38, compared to a current price of ₹8.69 — trading 265.1% above its estimated fair value. The current Research & Development is ₹0.00 Mil. Dolphin Medical Services' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current Research & Development is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?

Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued. The current stock price of ₹8.69 is trading 265.1% above its estimated GF Value™ of ₹2.38. GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.

Key valuation signals for BOM:526504:

  • Research & Development: ₹0.00 Mil
  • GF Value™: ₹2.38 vs. price of ₹8.69 (265.1% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dolphin Medical Services Business Description

Address Kovelamudivari Veedhi, D.No.29-28/1-27, Suryaraopet, Vijayawada, AP, IND, 520002
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
36GF Score

Get the complete analysis for BOM:526504

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8.69
Price
₹2.38
GF Value